Filing Details

Accession Number:
0000905148-16-001667
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-08 14:24:40
Reporting Period:
2016-06-06
Filing Date:
2016-06-08
Accepted Time:
2016-06-08 14:24:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1372218 Cpmg Inc 2000 Mckinney Ave., Ste 2125
Dallas TX 75201
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2016-06-06 1,090 $17.56 1,470 No 4 P Indirect By Crested Crane, LP
Class A Common Stock Acquisiton 2016-06-06 1,260 $17.56 1,700 No 4 P Indirect By Flamingo Fund, LP
Class A Common Stock Acquisiton 2016-06-06 1,610 $17.56 15,933 No 4 P Indirect By Mallard Fund, LP
Class A Common Stock Acquisiton 2016-06-06 4,580 $17.56 6,180 No 4 P Indirect By Gallopavo, LP
Class A Common Stock Acquisiton 2016-06-06 4,810 $17.56 6,490 No 4 P Indirect By Roadrunner Fund, LP
Class A Common Stock Acquisiton 2016-06-06 6,650 $17.56 8,980 No 4 P Indirect By Sandpiper Fund, LP
Class A Common Stock Acquisiton 2016-06-07 230 $17.62 1,700 No 4 P Indirect By Crested Crane, LP
Class A Common Stock Acquisiton 2016-06-07 270 $17.62 1,970 No 4 P Indirect By Flamingo Fund, LP
Class A Common Stock Acquisiton 2016-06-07 340 $17.62 16,273 No 4 P Indirect By Mallard Fund, LP
Class A Common Stock Acquisiton 2016-06-07 970 $17.62 7,150 No 4 P Indirect By Gallopavo, LP
Class A Common Stock Acquisiton 2016-06-07 1,010 $17.62 7,500 No 4 P Indirect By Roadrunner Fund, LP
Class A Common Stock Acquisiton 2016-06-07 1,400 $17.62 10,380 No 4 P Indirect By Sandpiper Fund, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Crested Crane, LP
No 4 P Indirect By Flamingo Fund, LP
No 4 P Indirect By Mallard Fund, LP
No 4 P Indirect By Gallopavo, LP
No 4 P Indirect By Roadrunner Fund, LP
No 4 P Indirect By Sandpiper Fund, LP
No 4 P Indirect By Crested Crane, LP
No 4 P Indirect By Flamingo Fund, LP
No 4 P Indirect By Mallard Fund, LP
No 4 P Indirect By Gallopavo, LP
No 4 P Indirect By Roadrunner Fund, LP
No 4 P Indirect By Sandpiper Fund, LP
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 150 Indirect By Blackwell Partners, LLC
Class A Common Stock 57,974 Indirect By Yellow Warbler, LP
Class A Common Stock 27,651 Indirect By Kestrel Fund, LP
Class A Common Stock 252,706 Indirect By Willet Fund, LP
Class A Common Stock 11,076 Indirect By CD Fund, LP
Class A Common Stock 134 Indirect By Redbird Life Sciences Partners, LP
Class A Common Stock 113 Direct
Footnotes
  1. This price reflects the weighted average purchase price for open-market purchases on June 6, 2016, within a $1.00 range. The actual prices for these transactions range from $17.2525 to $17.75, inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (1) through (2) to this Form 4.
  2. This price reflects the weighted average purchase price for open-market purchase orders placed by the Reporting Person with its broker on June 7, 2016, within a $1.00 range. The actual prices for these transactions range from $17.275 to $18.25, inclusive.
  3. The Reporting Person is the investment manager of each of: Blackwell Partners, LLC; Crested Crane, LP; Flamingo Fund, LP; Gallopavo, LP; Roadrunner Fund, LP; Sandpiper Fund, LP; Mallard Fund, LP; Yellow Warbler, LP; Kestrel Fund, LP; Willet Fund, LP; CD Fund, LP; and Redbird Life Sciences Partners, LP. The Reporting Person disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.